DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency - Wikidata - awgldk - TriplyDB

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

http://www.wikidata.org/entity/Q35210348

about

Antigen-specific immunotherapy of cervical and ovarian cancer An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.DNA vaccines for cervical cancer Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.Therapeutic HPV DNA vaccines.Perspectives for preventive and therapeutic HPV vaccines.Immunotherapy for cervical cancer: Research status and clinical potential Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice DNA vaccines for cervical cancer: from bench to bedside.Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell.Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection The future of vaccines for cervical cancer.Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency.Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.HPV Vaccines: today and in the Future.RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency.A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy Induction of multiple cytotoxic T lymphocyte responses in mice by a multiepitope DNA vaccine against dengue virus serotype 1.Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.Modified mRNA Vaccines Protect against Zika Virus Infection.DNA-Loaded Cationic Liposomes Efficiently Function as a Vaccine against Malarial Proteins.Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Predicting HLA CD4 Immunogenicity in Human Populations.Therapeutic human papillomavirus vaccines: current clinical trials and future directions

P2860

Q27488697-5DC11E2F-3FEB-45B3-98F6-B84FC1C5301B Q31121276-FC6E7B92-51F0-462A-8D1E-0330521C0947 Q33680693-33BBDFC6-EE7A-4AEF-8798-30E5B3F167D2 Q33698112-C3E6EA07-3746-45A5-AF35-D0BDCDD281A1 Q33860104-CE7AE824-D93A-4959-99F5-DE5B087EC128 Q33936427-503D85AE-3C81-4A21-9ECF-7974B164FD02 Q34011494-F096E9FD-36DF-488E-BB6F-EF417923EF67 Q34033763-EF00CF36-4A2F-470A-BFB2-231452B51EC7 Q34189966-C8139525-FCAA-4125-8AE0-9A66F2D2E262 Q34397856-637C2A89-66CF-42DE-B6F4-DE7740A309FA Q34544154-C90C311B-6C2F-40BD-B5DF-1795A1DB5B51 Q34708423-7B1DCBA9-5C11-485A-AD51-A1AB1FB8B4B9 Q34732491-4E41C9C0-7236-4991-8D6F-5FB40413863C Q34757847-CD21268B-D9C1-4FBE-822E-3F1C1CE442F4 Q34766642-69194D44-8D26-4E2B-A91C-6610EA034C94 Q35234992-90B58C76-98F8-403C-BE36-C5B16546878E Q35401109-150FE7FD-8553-44E1-BD61-09B9A0B105F2 Q35782004-B974A87A-69BD-45B6-9C47-999E40F39222 Q35785988-8B839B5A-87A8-487F-B8B7-326594A4FCCE Q35805491-8DF8EFFE-46DC-4AD2-B12C-2AF67749EE40 Q35838039-52B6CCFE-03C1-45B2-9C94-7152B64620C1 Q36248706-B5F56BF9-9379-4EA5-BE5A-1AE4C2A70070 Q36580268-E9089116-7F25-4901-A9B5-8D499AE13A8B Q36652548-54B0EA1D-EDF2-48D3-A962-76DD7AC029D5 Q36773225-49730080-0A07-4200-BD9C-C912D48D3047 Q36780146-4C16C171-C6B7-4617-8E79-B3791EAD5450 Q36976268-2A7DF38F-F72D-4D8A-A507-FCBC3898C056 Q36983827-3C5CA372-7EAB-41CA-9211-813280A4419E Q37272354-7A4D6FA4-E5B0-4EAA-B578-DE5E8D54C5D8 Q37771268-1FA2816F-CBB2-42E5-BB4F-F6A0A89CAED9 Q38942473-5BB30615-E2F4-4523-B51D-5675E85C5AFD Q39194082-4C766DE3-99C2-419C-A1D9-24A1BA419714 Q40049416-3C8CABDE-6F6B-4311-8A3F-F9F5A33194E8 Q41597451-8F06ABAF-1892-4645-A186-4E0F20F02029 Q47993135-6F7B486E-8164-4131-8DA3-A2760CD9E909 Q48371221-8EECFFDA-D5E8-42DF-A336-F5EDD1F119F0 Q50115667-B0312112-445F-4B76-964B-CE43E497F860 Q55383910-B47EFC26-9F5D-4098-905B-4B6BE60C041A Q56937332-A88E7B03-E998-4E88-B32C-4CDE6ABE58DA

P2860

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

http://www.wikidata.org/entity/Q35210348

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

DNA vaccines encoding Ii-PADRE ...... s and enhances vaccine potency

@ast

DNA vaccines encoding Ii-PADRE ...... s and enhances vaccine potency

@en

type

label

DNA vaccines encoding Ii-PADRE ...... s and enhances vaccine potency

@ast

DNA vaccines encoding Ii-PADRE ...... s and enhances vaccine potency

@en

prefLabel

DNA vaccines encoding Ii-PADRE ...... s and enhances vaccine potency

@ast

DNA vaccines encoding Ii-PADRE ...... s and enhances vaccine potency

@en

P1433

Q35210348-CCE0B283-3F13-49E6-8493-A11538798C9A

P1476

Q35210348-1C6A637C-60EF-4BAF-B63F-4DC81E2E4CFE

P2093

Q35210348-06F96AE3-FD4A-47EA-A940-5F5D09A21C98

Q35210348-0A28D4C7-1FB0-453F-9058-1F554059978B

Q35210348-297420F8-9F67-49DF-BBAC-8F0E6A8DC294

Q35210348-8EB4DAB1-D094-4C4F-B116-B626A7147732

P2860

Q35210348-03CAE92A-7892-4CA4-AE9F-4304A56FA9B8

Q35210348-0AB353B1-CF70-441E-8634-D309489621BC

Q35210348-1047AA11-C017-467F-9CD6-8A496246EA27

Q35210348-12C5CF26-0AD5-4DE7-93E9-D365BE771540

Q35210348-13E31133-3D85-4BCC-BD14-FA68E77A0392

Q35210348-151AB726-5D9F-4972-B99C-54D4E474D7F1

Q35210348-203C2D9C-A472-4859-B7BE-5047C3AABB2F

Q35210348-28D402D9-DFE1-4B50-AA1F-F5890C91CE7D

Q35210348-32757409-29B2-4B18-A0C8-E82569669C2A

Q35210348-334CCA98-0814-48EA-9DAE-F8B733F708A2

P304

Q35210348-662C2EA3-9B91-43DF-8C78-388583E41B9D

P31

Q35210348-9974DA0A-5345-4BD7-9274-88DCCF74FAA7

P356

Q35210348-A6855B6E-4A27-4BC5-A3F4-4654E0C66E9F

P433

Q35210348-44B9CCFF-B74B-436D-85CB-ACEC2B09D06B

P478

Q35210348-6BBBE8FF-0DAB-47BE-A835-5EF470F1BB1B

P577

Q35210348-FEC56534-A89A-4902-8199-3AA24EBF785C

P5875

Q35210348-39E90551-A3F1-408C-9EC4-E1780D5C59CF

P698

Q35210348-48201A10-C3DC-4D67-AE39-0FA96F0BC6D6

P932

Q35210348-84730C52-D261-4FC0-A865-416DBC3B20F8

P356

P1433

Molecular Therapy

P1476

DNA vaccines encoding Ii-PADRE ...... s and enhances vaccine potency

@en

P2093

Chien-Fu Hung

http://www.w3.org/2001/XMLSchema#string

Liangmei He

http://www.w3.org/2001/XMLSchema#string

T-C Wu

http://www.w3.org/2001/XMLSchema#string

Ya-Chea Tsai

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes

The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.

Role for intracellular proteases in the processing and transport of class II HLA antigens.

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class II-associated invariant chain peptide of the invariant chain

Improving DNA vaccine potency via modification of professional antigen presenting cells.

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope

Helping the CD8(+) T-cell response.

P304

1211-1219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.MT.6300121

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6449701

http://www.w3.org/2001/XMLSchema#string

P698

17356542

http://www.w3.org/2001/XMLSchema#string

P932

3171992

http://www.w3.org/2001/XMLSchema#string